Comparative Pharmacology
Head-to-head clinical analysis: NEBCIN versus TOBRAMYCIN.
Head-to-head clinical analysis: NEBCIN versus TOBRAMYCIN.
NEBCIN vs TOBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death. Exhibits concentration-dependent bactericidal activity.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
5-7 mg/kg IV once daily; 2-4 mg/kg/day IV divided every 8 hours for synergy; 2-4 mg/kg IM divided every 8 hours; 3-5 mg/kg/day IV for cystic fibrosis. Inhalation: 300 mg every 12 hours (nebulizer). Intrathecal: 5-20 mg/day.
None Documented
None Documented
Clinical Note
moderateTobramycin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Tobramycin."
Clinical Note
moderateTobramycin + Acetyldigitoxin
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
2–3 hours (normal renal function); prolonged to 24–60 hours in anuria. Clinical context: dosing interval must be adjusted for renal impairment to avoid accumulation and toxicity.
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Renal excretion of unchanged drug via glomerular filtration: >90% within 24 hours. Minimal biliary/fecal elimination (<5%).
Category C
Category D/X
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Tobramycin."